[EN] PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIDINE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2009024905A1
公开(公告)日:2009-02-26
The invention relates to novel pyridine derivatives of formula (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.
[EN] PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS<br/>[FR] DERIVES DE PYRIDINE ET LEUR UTILISATION COMME ANTAGONISTES DE L'UROTENSINE II
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2005030209A1
公开(公告)日:2005-04-07
The invention relates to novel pyridine derivatives of formula 1 and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and their use as neurohormonal antagonists, especially as urotensin II inhibitors.
Pyridin-4-yl derivatives as immunomodulating agents
申请人:Bolli Martin
公开号:US20100063108A1
公开(公告)日:2010-03-11
The invention relates to pyridine derivatives of Formula (I) wherein A, R
1
, R
2
, R
3
, R
4
, R
5
, and R
6
are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
The invention relates to novel pyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists.
The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.